GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CRISPR Therapeutics AG (NAS:CRSP) » Definitions » Cyclically Adjusted Book per Share

CRSP (CRISPR Therapeutics AG) Cyclically Adjusted Book per Share : $16.33 (As of Mar. 2025)


View and export this data going back to 2016. Start your Free Trial

What is CRISPR Therapeutics AG Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

CRISPR Therapeutics AG's adjusted book value per share for the three months ended in Mar. 2025 was $21.180. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $16.33 for the trailing ten years ended in Mar. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2025-07-09), CRISPR Therapeutics AG's current stock price is $59.57. CRISPR Therapeutics AG's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $16.33. CRISPR Therapeutics AG's Cyclically Adjusted PB Ratio of today is 3.65.

During the past 11 years, the highest Cyclically Adjusted PB Ratio of CRISPR Therapeutics AG was 3.58. The lowest was 2.00. And the median was 2.37.


CRISPR Therapeutics AG Cyclically Adjusted Book per Share Historical Data

The historical data trend for CRISPR Therapeutics AG's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CRISPR Therapeutics AG Cyclically Adjusted Book per Share Chart

CRISPR Therapeutics AG Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

CRISPR Therapeutics AG Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 16.33

Competitive Comparison of CRISPR Therapeutics AG's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, CRISPR Therapeutics AG's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CRISPR Therapeutics AG's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where CRISPR Therapeutics AG's Cyclically Adjusted PB Ratio falls into.


;
;

CRISPR Therapeutics AG Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, CRISPR Therapeutics AG's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book= Book Value per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=21.18/107.7224*107.7224
=21.180

Current CPI (Mar. 2025) = 107.7224.

CRISPR Therapeutics AG Quarterly Data

Book Value per Share CPI Adj_Book
201412 -0.179 100.704 -0.191
201509 0.000 99.785 0.000
201512 -0.732 99.386 -0.793
201603 0.000 99.475 0.000
201606 3.405 100.088 3.665
201609 -1.572 99.604 -1.700
201612 5.862 99.380 6.354
201703 5.405 100.040 5.820
201706 4.940 100.285 5.306
201709 4.376 100.254 4.702
201712 4.627 100.213 4.974
201803 6.220 100.836 6.645
201806 5.633 101.435 5.982
201809 8.095 101.246 8.613
201812 7.564 100.906 8.075
201903 7.216 101.571 7.653
201906 6.873 102.044 7.255
201909 10.725 101.396 11.394
201912 15.455 101.063 16.473
202003 14.552 101.048 15.513
202006 14.219 100.743 15.204
202009 19.026 100.585 20.376
202012 22.516 100.241 24.197
202103 23.841 100.800 25.478
202106 34.225 101.352 36.376
202109 32.865 101.533 34.869
202112 31.166 101.776 32.987
202203 29.009 103.205 30.279
202206 26.877 104.783 27.631
202209 24.971 104.835 25.659
202212 23.888 104.666 24.586
202303 23.520 106.245 23.847
202306 22.880 106.576 23.126
202309 21.753 106.570 21.988
202312 23.522 106.461 23.801
202403 24.564 107.355 24.648
202406 23.293 107.991 23.235
202409 22.730 107.468 22.784
202412 22.534 107.128 22.659
202503 21.180 107.722 21.180

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


CRISPR Therapeutics AG  (NAS:CRSP) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

CRISPR Therapeutics AG's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=59.57/16.33
=3.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 11 years, the highest Cyclically Adjusted PB Ratio of CRISPR Therapeutics AG was 3.58. The lowest was 2.00. And the median was 2.37.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


CRISPR Therapeutics AG Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of CRISPR Therapeutics AG's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


CRISPR Therapeutics AG Business Description

Industry
Traded in Other Exchanges
Address
Baarerstrasse 14, Zug, CHE, CH-6300
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Executives
Raju Prasad officer: Chief Financial Officer CRISPR THERAPEUTICS, INC., 105 W FIRST STREET, BOSTON MA 02127
Samarth Kulkarni officer: Chief Business Officer C/O CRISPR THERAPEUTICS AG, 200 SIDNEY STREET, CAMBRIDGE MA 02139
James R. Kasinger officer: General Counsel and Secretary C/O CRISPR THERAPEUTICS, INC., 610 MAIN STREET, CAMBRIDGE MA 02139
John Greene director 51 LIME STREET, LONDON X0 EC3M 7DQ
Phuong Khanh Morrow officer: Chief Medical Officer C/O CRISPR THERAPEUTICS, 610 MAIN STREET, CAMBRIDGE MA 02139
Maria Fardis director C/O PARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Brendan Smith officer: Chief Financial Officer 29 HARTWELL AVENUE, LEXINGTON MA 02421
Michael John Tomsicek officer: Chief Financial Officer 28 OVERLOOK DRIVE, BEDFORD MA 01730
Bolzon Bradley J Phd director ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Rodger Novak director, officer: Chief Executive Officer C/O CRISPR THERAPEUTICS AG, 200 SIDNEY STREET, CAMBRIDGE MA 02139
Harold Edward Fleming director C/O CRISPR THERAPEUTICS AG, 610 MAIN STREET, CAMBRIDGE MA 02139
Lawrence Otto Klein officer: Chief Business Officer C/O CRISPR THERAPEUTICS AG, 610 MAIN STREET 7TH FLOOR, CAMBRIDGE MA 02139
Tony W Ho officer: See Remarks CRISPR THERAPEUTICS AG, 610 MAIN STREET, CAMBRIDGE MA 02139
Douglas A Treco director 87 CAMBRIDGEPARK DRIVE, C/O RA PHARMACEUTICALS, INC., CAMBRIDGE MA 02140
Pablo J Cagnoni director ONYX PHARMACEUTICALS, INC., 249 E. GRAND AVE., SOUTH SAN FRANCISCO CA 94080